| Literature DB >> 27537070 |
Michelle M Lusardi1, Stacy Fritz, Addie Middleton, Leslie Allison, Mariana Wingood, Emma Phillips, Michelle Criss, Sangita Verma, Jackie Osborne, Kevin K Chui.
Abstract
BACKGROUND: Falls and their consequences are significant concerns for older adults, caregivers, and health care providers. Identification of fall risk is crucial for appropriate referral to preventive interventions. Falls are multifactorial; no single measure is an accurate diagnostic tool. There is limited information on which history question, self-report measure, or performance-based measure, or combination of measures, best predicts future falls.Entities:
Mesh:
Year: 2017 PMID: 27537070 PMCID: PMC5158094 DOI: 10.1519/JPT.0000000000000099
Source DB: PubMed Journal: J Geriatr Phys Ther ISSN: 1539-8412 Impact factor: 3.381
Measures Used as Search Terms and Additional Measures Identified During Review of Retrieved Articlesa
| Included | Excluded |
|---|---|
| Self-report measures Activity-Specific Balance Confidence (ABC) Barthel Index (BI) Center for Epidemiological Studies Depression Scale (CES-D) Fall Efficacy Scale International (FES-I) Geriatric Depression Scale (GDS) Medical Outcomes Study Short Form (SF-36) Mini-Mental State Evaluation (MMSE) 30-s sit to stand Berg Balance Scale (BBS) Dynamic gait index (DGI) 5 times sit-to-stand time (5TSTS) 1 time Sit-to-stand time (OTSTS) Fullerton Advanced Balance Scale (FAB) Functional Reach Distance (FR) Modified Clinical Test of Sensory Interaction and Balance (mCTSIB) Performance-Oriented Mobility Assessment (POMA-Tinetti) Physical Performance Test (PPT) Romberg Test/Sharpened Romberg/Tandem Stance Self-selected walking speed/10-m walk (SSWS) Single-limb stance/one-leg stance/unipedal stance (SLS) Timed Up and Go (TUG) | Self-report measures
Dizziness Handicap Inventory (DHI) Fear Avoidance Beliefs Questionnaire Functional Gait Assessment Home and Community Environment Questionnaire History of Falls Questionnaire Lower Extremity Functional Scale Patient Specific Functional Scale Rivermead Mobility Index WHO Quality of Life-BREF (WHOQOL-BREF) 2-min walk distance 6-min walk distance 360° Turn Test Balance Evaluation Systems (BEST) Test, mini Best Test Brunell Balance Assessment Test Canadian Occupational Performance Measure Continuous Scale Physical Functional Performance Test Fast Walking Speed (FWS) Functional Independence Measure (FIM) Four-Square Step Test (FSST) High-Level Mobility Assessment Tool Multidirectional Reach Test Push and Release Test Sensory Organization Test (SOT) Timed Backward Walk Walking while talking Test |
| History questions
Age > 80 y (yes/no) Alcohol use (yes/no) Ambulatory assistive device (AD) use (yes/no) Dependence in activities of daily living (yes/no) History of previous falls (yes/no) Nocturia/urgency/incontinence (yes/no) Polypharmacy (yes/no) Psychoactive medication use (yes/no) Self-reported depression (yes/no) Self-Reported difficulty walking Self-reported fear of falling (yes/no) Self-reported imbalance (yes/no) Self-reported physical activity/exercise Self-reported health status Self-reported pain Balance Self-Perception Test Falls Risk Assessment Questionnaire Longitudinal Study of Aging Physical Activity Questionnaire Older Adults Resources and Services (OARS) ADL scale Self-Rated Health Questionnaire Subjective Ratings of Specific Tasks Short Orientation Memory Concentration Test Sickness Impact Profile (SIP) Ability to sit to stand without upper extremity support (yes/no) Alternate Step Test Half-turn test (# steps) Maximum step length Minimal chair height Modified Gait Abnormality Rating Scale (mGARS) Physiological Profile Assessment (PPA) Pick up 5 lb weight test Spring Scale Test 8-Stairs ascend/descend time Stride length Tandem walk (able/unable) | Self-report measures Balance Efficacy Scale Community Balance and Mobility Scale Demura Fall Risk Assessment Fall Assessment and Intervention Record Falls Behavioral Scale for Old People Fall Risk Assessment Tool for Older People Fall Risk Assessment Tool Falls Assessment Risk and Management Tool Fall risk by exposure Fall Risk Questionnaire Fear of Falling Avoidance Questionnaire Gait Efficacy Scale Goal Attainment Scale Hauser Ambulation Index Hendrich II Fall Risk Model Home Falls and Accidents Screening Tool 21-item Fall Risk Index Alternate Step Test Body mass index Cadence Figure-8 Walking Test Grip strength Get up and go (untimed) Lateral Reach Test Lateral Reach Test Lower extremity strength Melbourne Fall Risk Assessment Tool Morse Fall Scale Motor Fitness Scale Obstacle course Peninsula Health Fall Risk Assessment Tool Queensland Fall Risk Assessment Tool Short Physical Performance Battery St. Thomas Risk Assessment Tool (Stratefy) STEADI Stance and Swing (time and %) Gait cycle time Step Up Test Trail Walking Test |
aIn order for a measure to be included in analysis, data extracted from research articles about the measure had to include number of participants who did/did not fall, the value of a threshold or cut score for the measure, and/or reported sensitivity and specificity values, such that posttest probability (PoTP) could be calculated.
bSufficient information for calculation of PoTP.
cInsufficient information for CALCULATION of PoTP.
Figure 1.Usefulness of a 2 × 2 table for interpreting test results. In this systematic review and meta-analysis, data about each test from multiple studies were combined to calculate an overall sensitivity and specificity values, and positive (+ LR) and negative (− LR) likelihood ratios. On the basis of consistent epidemiological evidence, pretest probability for future falls was set at 30%. Calculation of pretest odds from pretest probability, followed by calculation of posttest odds, allows estimation of posttest probability. Assuming a moderate effect + LR of 5 and − LR of 0.5, posttest probability after a positive test would increase from 30% to 68%. Assuming a moderate effect − LR of 0.5, posttest probability after a negative test would decrease from 30% to 18%. When test results are positive, the size of the increase in posttest probability beyond pretest predictive toward 100% determines how much “more sure” the clinician can be that an older adult would likely experience a future fall. When test results are negative, how much posttest probability decreases toward 0 from pretest value determines how much “more sure” that an older individual would not be likely to fall.
Figure 2.PRISMA diagram for the systematic review process. A total of 2294 abstracts were reviewed; these included 500 duplicates and 1430 that did not immediately meet inclusion criteria. A total of 364 full-text articles were retrieved, examined, and appraised: an additional 269 did not meet inclusion criteria. Data were extracted from the remaining 95 articles; 57 of these contained information necessary for calculation of posttest probability.
Summary of Findings for Determining Risk of Falls During Patient Medical History Component of the Physical Therapy Examinationa
| History Questions | Author | Level | QUADAS Score | Study Type, mo | Fall Defined | Age, Mean (SD) | Fallers, N | Nonfallers, N | Cut Point | Fallers With +Test | Non Fallers With −Test | Difference | Sn (CI95), % | Sp (CI95), % | +LR (CI95) | −LR (CI95) | Posttest Probability, % | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| If +Test | If −Test | |||||||||||||||||
| Activities of daily living (ADL) | Kwan et al | I | 84.6 | Pro (24) | Fall inj/≥2 falls | 74.9 (6.4) | 86 | 174 | 2 IADL depend | 14 | 157 | NR | 16 (9-26) | 90 (85-94) | 1.7 (0.9-3.2) | 0.9 (0.8-1.0) | 42 | 28 |
| Muir et al | I | 84.6 | Pro (12) | Any fall | 79.7 (5.3) | 59 | 58 | Any ADL depend | 12 | 52 | NR | 20 (11-33) | 90 (79-96) | 2.0 (0.8-4.9) | 0.9 (0.8-1.0) | 46 | 28 | |
| Tinetti et al | I | 76.9 | Pro (12) | Any fall | 76.9 (5.3) | 546 | 557 | Any ADL depend | 364 | 251 | ANOVA | 67 (62-71) | 45 (41-49) | 1.2 (1.1-1.3) | 0.7 (0.6-0.9) | 34 | 23 | |
| Muir et al | I | 76.9 | Pro (12) | Any fall | 79.9 (4.7) | 78 | 104 | Any ADL depend | 7 | 100 | NR | 9 (4-18) | 96 (90-99) | 2.3 (0.7-7.7) | 1.0 (0.9-1.0) | 50 | 30 | |
| Coll-Planas et al | I | 76.9 | Pro (12) | Any fall | 82 (NR) | 116 | 76 | Bathing depend | 74 | 44 | OR = 2.4 | 64 (54-73) | 58 (46-69) | 1.5 (1.1-2.0) | 0.6 (0.5-0.9) | 39 | 20 | |
| Walking outside | 51 | 51 | OR = 1.6 | 44 (35-53) | 67 (55-77) | 1.3 (0.9-2.0) | 0.8 (0.7-1.1) | 36 | 26 | |||||||||
| Dressing depend | 34 | 60 | OR = 1.6 | 29 (21-38) | 79 (68-87) | 1.4 (0.8-2.3) | 0.9 (0.8-1.1) | 38 | 28 | |||||||||
| Transfer depend | 13 | 75 | OR = 9.5 | 11 (6-18) | 99 (93-100) | 8.5 (1.1-64) | 0.9 (0.8-1.0) | 78 | 28 | |||||||||
| Stairs depend | 31 | 72 | OR = 2.2 | 27 (19-36) | 95 (87-99) | 5.1 (1.9-14) | 0.8 (0.7-0.9) | 69 | 26 | |||||||||
| Hellstrom et al | III | 100 | Retro (6) | Any fall | 81.7 (4.8) | 81 | 297 | Any ADL depend | 37 | 258 | χ2 | 47 (36-58) | 87 (83-90) | 3.6 (2.5-5.2) | 0.6 (0.5-0.8) | 61 | 20 | |
| Flemming | III | 69.2 | Retro (4) | Any fall | 78.7 (7.2) | 40 | 267 | Any ADL depend | 37 | 75 | χ2 | 93 (79-98) | 29 (23-34) | 1.3 (1.2-1.4) | 0.3 (0.1-0.8) | 36 | 11 | |
| 1006 | 1533 | Any ADL depend | 545 | 937 | NA | 54 (51-57) | 61 (59-64) | 1.4 (1.3-1.5) | 0.8 (0.7-0.8) | 38 | 26 | |||||||
| Age | Stalenhoef et al | I | 84.6 | Retro (12) | Any fall | M: 77.2 (4.9) | 207 | 104 | ≥80 | 84 | 63 | NR | 41 (34-48) | 61 (51-70) | 1.0 (0.8-1.4) | 1.0 (0.9-1.2) | 30 | 30 |
| Yamada and Iscihashi | I | 84.6 | Retro (12) | Any fall | 80.5 (5.6) | 59 | 112 | ≥80 | 34 | 41 | NR | 58 (44-70) | 37 (28-46) | 0.9 (0.7-1.2) | 1.2 (0.8-1.7) | 28 | 34 | |
| LeClerc et al | II | 76.9 | Pro (6) | ≥2 falls | F: 79.5 (6.6) | 99 | 769 | ≥75 | 72 | 185 | 73 (63-81) | 24 (21-27) | 1.0 (0.8-1.1) | 1.1 (0.8-1.6) | 30 | 32 | ||
| Sohng et al | III | 92.3 | Retro (12) | Any fall | 73.3 (6.1) | 148 | 203 | ≥75 | 50 | 118 | NR | 34 (26-42) | 58 (51-65) | 0.8 (0.6-1.1) | 1.1 (1.0-1.3) | 23 | 32 | |
| Payne et al | III | 92.3 | Retro (12) | Any fall | R: 75.5 (7.7) | 34 | 81 | ≥80 | 11 | 10 | NR | 32 (17-51) | 79 (69-87) | 1.5 (0.8-2.9) | 0.9 (0.7-1.1) | 39 | 28 | |
| 547 | 1269 | >80 | 251 | 471 | NA | 46 (42-50) | 37 (34-40) | 0.7 (0.7-0.8) | 1.5 (1.3-1.6) | 23 | 39 | |||||||
| Ambulatory assistive device use | Sai et al | I | 92.3 | Pro (12) | Any fall | 76.7 (6.1) | 95 | 42 | Yes | 30 | 40 | χ2 | 32 (22-42) | 95 (84-99) | 6.6 (1.7-26.0) | 0.7 (0.6-0.8) | 74 | 23 |
| Brauer et al | I | 84.6 | Pro (6) | Any fall | 71 (5) | 35 | 65 | Yes | 2 | 60 | χ2 | 6 (1-19) | 92 (83-97) | 0.7 (0.2-3.6) | 1.0 (0.9-1.1) | 23 | 30 | |
| Kwan et al | I | 84.6 | Pro (24) | Any fall | 74.9 (6.4) | 86 | 174 | Yes | 15 | 165 | NR | 17 (10-27) | 95 (90-98) | 3.4 (1.5-7.4) | 0.9 (0.8-1.0) | 59 | 28 | |
| Muir et al | I | 84.6 | Pro (12) | Any fall | 79.7 (5.3) | 59 | 58 | Yes | 15 | 50 | NR | 28 (16-42) | 86 (75-94) | 2.0 (0.9-4.4) | 0.8 (0.7-1.0) | 46 | 28 | |
| Tinetti et al | I | 84.6 | Pro (12) | Any fall | 76.9 (5.3) | 546 | 557 | Yes | 80 | 512 | ANOVA | 15 (12-18) | 92 (89-94) | 1.9 (1.3-2.6) | 0.9 (0.9-1.0) | 45 | 28 | |
| Yamada and Iscihashi | I | 84.6 | Pro (12) | Any fall | 80.5 (5.6) | 59 | 112 | Yes | 5 | 99 | χ2 | 9 (3-19) | 88 (81-94) | 0.7 (0.3-2.0) | 1.0 (0.0-1.2) | 23 | 30 | |
| Muir et al | I | 76.9 | Pro (12) | Any fall | 79.9 (4.7) | 78 | 104 | Yes | 12 | 93 | NR | 15 (8-25) | 90 (83-95) | 1.5 (0.7-3.2) | 0.9 (0.8-1.1) | 39 | 28 | |
| Hellstrom et al | III | 100 | Retro (6) | Any fall | 81.7 (4.8) | 81 | 297 | Yes | 45 | 223 | χ2 | 56 (44-67) | 75 (70-80) | 2.2 (1.7-2.9) | 0.6 (0.5-0.8) | 49 | 20 | |
| Shumway-Cook et al | III | 84.5 | Retro (6) | Any fall | F: 86.2 (6.4) | 15 | 15 | Yes | 12 | 15 | NR | 80 (52-96) | 100 (78-100) | NA | 0.2 (0.1-0.6) | NA | 8 | |
| Desai et al | III | 76.9 | Retro (12) | Any fall | F 81.5 (6.9) | 47 | 25 | Yes | 35 | 7 | χ2 | 74 (60-86) | 28 (12-49) | 1.0 (0.8-1.4) | 0.9 (0.4-2.0) | 30 | 28 | |
| Huang | III | 76.9 | Retro (12) | Any fall | 76 (NR) | 199 | 197 | Yes | 92 | 138 | χ2 | 46 (39-53) | 70 (63-76) | 1.5 (1.2-2.0) | 0.8 (0.7-0.9) | 39 | 26 | |
| Shumway-Cook et al | III | 76.9 | Retro (6) | ≥2 falls | 78.7 (7.2) | 22 | 22 | Yes | 5 | 22 | χ2 | 23 (8-45) | 100 (85-100) | NA | 0.8 (0.6-1.0) | NA | 26 | |
| Flemming | III | 69.2 | Pro (4) | Any fall | 78.7 (7.2) | 40 | 267 | Yes | 37 | 77 | χ2 | 93 (80-98) | 29 (24-35) | 1.3 (1.2-1.5) | 0.3 (0.1-0.8) | 36 | 11 | |
| 1362 | 1935 | Yes | 385 | 1501 | NA | 28 (26-31) | 78 (76-79) | 1.3 (1.1-1.4) | 0.9 (0.9-1.0) | 36 | 26 | |||||||
| Alcohol consumption | Sai et al | I | 92.3 | Pro (12) | Any fall | 76.7 (6.1) | 95 | 42 | Yes | 46 | 18 | NR | 48 (38-59) | 43 (28-59) | 0.9 (0.6-1.2) | 1.2 (0.8-1.8) | 28 | 34 |
| Bongue et al | I | 84.6 | Pro (12) | 70.7 (4.6) | 563 | 1196 | Yes | 509 | 101 | NR | 90 (88-93) | 8 (7-10) | 1.0 (1.0-1.0) | 1.1 (0.8-1.5) | 30 | 32 | ||
| Swanenburg et al | I | 76.9 | Pro (12) | ≥2 falls | 73.7 (7) | 85 | 185 | Daily | 27 | 154 | NR | 32 (22-43) | 83 (77-88) | 1.9 (1.2-3.0) | 0.8 (0.7-1.0) | 45 | 26 | |
| LeClerc et al | II | 76.9 | Pro (6) | ≥2 falls | F: 79.5 (6.6) | 769 | 99 | Yes | 155 | 78 | χ2 | 20 (17-23) | 79 (69-86) | 1.0 (0.6-1.4) | 1.0 (0.9-1.1) | 30 | 30 | |
| Sohng et al | III | 92.3 | Retro (12) | Any fall | 73.3 (6.1) | 148 | 203 | Yes | 61 | 111 | χ2 | 41 (33-50) | 55 (48-62) | 0.9 (0.7-1.2) | 1.1 (0.9-1.3) | 28 | 32 | |
| Payne et al | III | 92.3 | Retro (12) | Any fall | R: 75.5 (7.7) | 34 | 81 | Yes | 11 | 49 | NR | 32 (17-51) | 61 (49-71) | 0.8 (0.5-1.4) | 1.1 (0.8-1.5) | 28 | 32 | |
| Huang | III | 76.9 | Retro (12) | Any fall | F: 81.3 (5.1) | 200 | 201 | Yes | 18 | 175 | χ2 | 9 (5-14) | 87 (82-91) | 0.7 (0.4-1.2) | 1.1 (1.0-1.1) | 23 | 32 | |
| 1894 | 2007 | Yes | 827 | 686 | NA | 44 (41-46) | 34 (32-36) | 0.7 (0.6-0.7) | 1.7 (1.6-1.8) | 23 | 42 | |||||||
| Depression | Muir et al | I | 84.6 | Pro (12) | Any fall | 79.7 (5.3) | 59 | 58 | Yes | 16 | 48 | NR | 27 (16-40) | 83 (71-91) | 1.6 (0.8-3.2) | 0.9 (0.7-1.1) | 41 | 28 |
| Difficulty walking or missteps Self-report | Srygley et al | I | 84.6 | Pro | Any fall | 76.4 (4.3) | 68 | 198 | ≥2 missteps | 9 | 177 | NR | 13 (6-24) | 89 (84-93) | 1.3 (0.6-2.6) | 1.0 (0.9-1.1) | 36 | 30 |
| Sohng et al | III | 92.3 | Retro (12) | Any fall | 73.3 (6.1) | 148 | 203 | Difficulty walking | 71 | 128 | χ2 | 48 (40-56) | 63 (56-70) | 1.3 (1.0-1.7) | 0.8 (0.7-1.0) | 36 | 23 | |
| 216 | 401 | Difficulty walking | 80 | 305 | NA | 37 (931-44) | 76 (72-80) | 1.6 (1.2-2.0) | 0.8 (0.7-0.9) | 41 | 26 | |||||||
| Fear of falling | Coll-Planas et al | I | 76.9 | Pro (12) | Any fall | 82 (NR) | 116 | 76 | Yes | 33 | 63 | OR = 1.9 | 28 (20-38) | 83 (73-91) | 1.7 (0.9-3.0) | 0.9 (0.7-1.0) | 42 | 28 |
| Muir et al | I | 84.6 | Pro (12) | Any fall | 79.7 (5.3) | 59 | 58 | Yes | 20 | 47 | NR | 34 (22-47) | 81 (69-90) | 1.8 (0.9-3.4) | 0.8 (0.7-1.0) | 44 | 26 | |
| Muir et al | I | 76.9 | Pro (12) | Any fall | 79.9 (4.7) | 78 | 104 | Yes | 11 | 97 | NR | 14 (7-24) | 93 (87-97) | 2.1 (0.9-5.2) | 0.9 (0.8-1.0) | 47 | 28 | |
| Swanenburg et al | I | 76.9 | Pro (12) | ≥2 falls | 73.7 (7) | 85 | 185 | Yes | 24 | 149 | NR | 28 (19-39) | 81 (74-86) | 1.5 (0.9-2.3) | 0.9 (0.8-1.0) | 39 | 28 | |
| Hellstrom et al | III | 100 | Retro (6) | Any fall | 81.7 (4.8) | 81 | 297 | Yes | 48 | 219 | χ2 | 60 (48-70) | 70 (68-79) | 2.3 (1.7-2.9) | 0.6 (0.4-0.7) | 50 | 20 | |
| Keskin et al | III | 84.6 | Retro | Any fall | F: 68 (3) NF: 70 (5) | 12 | 19 | Yes | 5 | 18 | χ2 | 42 (15-72) | 95 (74-100) | 7.9 (1.1-60) | 0.6 (0.4-1.0) | 77 | 20 | |
| Flemming | III | 69.2 | Retro (4) | Any fall | 78.7 (7.2) | 40 | 267 | Yes | 24 | 165 | χ2 | 60 (43-75) | 62 (56-68) | 1.6 (1.2-2.1) | 0.7 (0.4-1.0) | 41 | 23 | |
| 471 | 1006 | Yes | 165 | 758 | NA | 35 (31-40) | 75 (73-78) | 1.4 (1.2-1.7) | 0.9 (0.8-0.9) | 38 | 28 | |||||||
| Health status | Kwan et al | I | 84.6 | Pro (24) | Any fall | 74.9 (6.4) | 86 | 174 | ≤ fair | 69 | 49 | IRR = 1.55 | 80 (70-88) | 28 (22-35) | 1.1 (1.0-1.3) | 0.7 (0.4-1.1) | 32 | 23 |
| Muir et al | I | 84.6 | Pro (12) | Any fall | 79.7 (5.3) | 59 | 58 | ≤ fair | 12 | 38 | NR | 20 (11-33) | 66 (52-78) | 0.6 (0.3-1.1) | 1.2 (2.0-1.1) | 20 | 34 | |
| Iinattiniemi et al | II | 69.2 | Pro (11) | Any fall | F: 88(3) NF: 88 (2) | 273 | 282 | ≤ fair | 49 | 242 | χ2 | 18 (14-23) | 86 (81-90) | 1.3 (0.9-1.9) | 1.0 (0.9-1.0) | 36 | 30 | |
| 418 | 514 | ≤ fair | 130 | 329 | NA | 31 (27-36) | 64 (60-68) | 0.9 (0.7-1.0) | 1.1 (1.0-1.2) | 28 | 32 | |||||||
| History of falling Self-report | Aoyama et al | I | 92.3 | Pro (6) | Any fall | 80.5 (5.7) | 25 | 33 | Any fall | 18 | 13 | NR | 72 (51-88) | 39 (23-58) | 1.2 (0.8-1.7) | 0.7 (0.3-1.5) | 34 | 23 |
| Herman et al | I | 92.3 | Pro (24) | Any fall | 76.3 (6.1) | 131 | 131 | Any fall | 46 | 116 | χ2 | 35 (27-44) | 89 (82-93) | 3.1 (1.8-5.2) | 0.7 (0.6-0.8) | 57 | 23 | |
| Lindeman et al | I | 92.3 | Pro (12) | Any fall | F: 68.8 (6.0) | 30 | 26 | Any fall | 19 | 20 | χ2 | 63 (43-80) | 77 (56-91) | 2.7 (1.3-5.8) | 0.5 (0.3-0.8) | 54 | 18 | |
| Sai et al | I | 92.3 | Pro (12) | Any fall | 76.7 (6.1) | 95 | 42 | Any fall | 54 | 26 | OR = 3.8 | 57 (46-67) | 62 (46-76) | 1.5 (1.0-2.3) | 0.7 (0.5-1.0) | 39 | 23 | |
| Bongue et al | I | 84.6 | Pro (12) | Any fall | 70.7 (4.6) | 563 | 1196 | Any fall | 236 | 965 | NR | 42 (38-46) | 81 (78-83) | 2.2 (1.9-2.5) | 0.7 (0.7-0.8) | 49 | 23 | |
| Brauer et al | I | 84.6 | Pro (6) | Any fall | 71 (5) | 35 | 65 | Any fall | 19 | 49 | χ2 | 54 (37-71) | 75 (63-85) | 2.2 (1.3-3.7) | 0.6 (0.4-0.9) | 49 | 20 | |
| Kwan et al | I | 84.6 | Pro (24) | Any fall | 74.9 (6.4) | 86 | 174 | Any fall | 33 | 135 | NR | 38 (28-50) | 78 (71-84) | 1.7 (1.2-2.5) | 0.8 (0.7-1.0) | 42 | 26 | |
| Muir et al | I | 84.6 | Pro (12) | Any fall | 79.7 (5.3) | 59 | 58 | Any fall | 34 | 58 | NR | 58 (44-70) | 100 (93-100) | NA | 0.4 (0.3-0.6) | NA | 15 | |
| Panzer et al | I | 84.6 | Pro (12) | ≥2 falls | F: 80.1 (6.2) | 39 | 23 | ≥2 falls | 23 | 6 | χ2 | 59 (42-74) | 26 (10-48) | 0.8 (0.6-1.1) | 1.6 (0.7-3.4) | 26 | 41 | |
| Stalenhoef et al | I | 84.6 | Pro (9) | ≥2 falls | M: 77.2 (4.9) | 46 | 192 | Any fall | 7 | 133 | OR = 3.0 | 15 (6-29) | 69 (62-75) | 0.5 (0.3-1.0) | 0.6 (0.5-0.7) | 68 | 20 | |
| Coll-Planas et al | I | 76.9 | Pro (12) | Any fall | 82 (NR) | 116 | 76 | Any fall | 93 | 31 | OR = 1.8 | 80 (72-87) | 41 (30-53) | 1.4 (1.1-1.7) | 0.5 (0.3-0.8) | 38 | 18 | |
| LeClerc et al | I | 76.9 | Pro (6) | ≥2 falls | F: 79.5 (6.6) | 99 | 769 | ≥2 falls | 65 | 496 | χ2 | 66 (55-75) | 65 (61-68) | 1.9 (1.6-2.2) | 0.5 (0.4-0.7) | 45 | 18 | |
| Muir et al | I | 76.9 | Pro (12) | Any fall | 79.9 (4.7) | 78 | 104 | Any fall | 31 | 89 | NR | 40 (29-51) | 86 (77-92) | 2.8 (1.6-4.7) | 0.7 (0.6-0.9) | 55 | 23 | |
| Swanenburg et al | I | 76.9 | Pro (12) | ≥2 falls | 73.7 (7) | 85 | 185 | ≥2 falls | 23 | 173 | NR | 27 (18-38) | 93 (89-96) | 4.2 (2.2-8.0) | 0.8 (0.7-0.9) | 64 | 26 | |
| Buatois et al | II | 69.2 | Pro (18) | ≥2 falls | 70.1 (4.4) | 96 | 903 | ≥2 falls | 53 | 743 | χ2 | 55 (45-65) | 82 (80-85) | 3.1 (2.5-3.9) | 0.5 (0.4-0.7) | 57 | 18 | |
| Flemming | II | 69.2 | Pro (4) | Any fall | 78.7 (7.2) | 40 | 267 | Any fall | 27 | 152 | χ2 | 68 (51-81) | 57 (51-63) | 1.6 (1.2-2.0) | 0.6 (0.4-0.9) | 41 | 20 | |
| Gerdhem et al | II | 69.2 | Pro (12) | Any fall | F: 75 (NR) | 232 | 746 | Any fall | 103 | 585 | OR = 2.9 | 44 (38-51) | 78 (75-81) | 2.1 (1.7-2.5) | 0.7 (0.6-0.8) | 47 | 23 | |
| Iinattiniemi et al | II | 69.2 | Pro (11) | Any fall | F: 88 (3) | 273 | 282 | ≥2 falls | 88 | 243 | χ2 | 32 (27-38) | 86 (82-90) | 2.3 (1.7-3.3) | 0.8 (0.7-0.9) | 50 | 26 | |
| Myers et al | III | 86.5 | Retro (12) | Any fall | 74.5 (8.3) | 17 | 20 | Any fall | 14 | 15 | χ2 | 82 (57-96) | 75 (51-91) | 3.3 (1.5-7.3) | 0.2 (0.1-0.7) | 59 | 8 | |
| 2109 | 5292 | Any fall | 906 | 4047 | NA | 43 (41-45) | 77 (75-78) | 1.8 (1.7-2.0) | 0.8 (0.7-0.8) | 44 | 26 | |||||||
| History of imbalance | Shumway-Cook et al | III | 76.9 | Retro (6) | ≥2 falls | 78.7 (7.2) | 22 | 22 | Yes | 21 | 9 | χ2 | 95 (77-100) | 59 (36-79) | 2.3 (1.4-3.9) | 0.1 (0.0-0.5) | 50 | 4 |
| Limited physical activity or exercise Self-report | Kwan et al | I | 84.6 | Pro (24) | Fall inj/≥2 falls | 74.9 (6.4) | 86 | 174 | Avoid stairs | 54 | 97 | NR | 63 (52-73) | 56 (48-63) | 1.4 (1.1-1.8) | 0.7 (0.5-0.9) | 38 | 23 |
| Swanenburg et al | I | 76.9 | Pro (12) | 2+ falls | 73.7 (7) | 85 | 185 | Sedentary | 8 | 171 | NR | 9 (4-18) | 92 (88-96) | 1.2 (.5-2.8) | 1.0 (0.9-1.1) | 30 | 30 | |
| Tinetti et al | I | 84.6 | Pro (12) | Any fall | 76.9 (5.3) | 546 | 557 | Walk <3 blocks/d | 329 | 288 | ANOVA | 60 (56-64) | 52 (48-56) | 1.3 (1.1-1.4) | 0.8 (0.7-0.9) | 36 | 26 | |
| Hellstrom et al | III | 100 | Retro (6) | Any fall | 81.7 (4.8) | 81 | 297 | <3 h | 58 | 164 | χ2 | 72 | 55 | 1.6 | 0.5 | 41 | 18 | |
| Sohng et al | III | 92.3 | Retro (12) | Any fall | 73.3 (6.1) | 148 | 203 | Stayed home | 42 | 138 | NR | 28 (21-36) | 68 (61-74) | 0.9 (0.6-1.2) | 1.1 (0.9-1.2) | 26 | 32 | |
| Karlsson et al | III | 77.9 | Retro (12) | ≥2 falls | 75 (NR) | 2049 | 8928 | No exercise | 1443 | 3108 | Regression | 70 (68-72) | 35 (34-36) | 1.1 (1.1-1.1) | 0.8 (0.8-0.9) | 32 | 26 | |
| No HHW | 738 | 6071 | Regression | 36 (34-38) | 70 (69-71) | 1.2 (1.1-1.3) | 0.9 (0.9-0.9) | 34 | 28 | |||||||||
| Iinattiniemi et al | III | 69.2 | Retro (11) | Any fall | 88 (2) | 273 | 282 | Sedentary | 81 | 219 | χ2 | 30 (24-35) | 78 (72-82) | 1.3 (1.0-1.8) | 0.9 (0.8-1.0) | 36 | 28 | |
| Rosengren et al | III | 64.2 | Retro (12) | Any fall | F: 74.8 (NR) | 1918 | 8912 | No exercise | 1283 | 2683 | χ2 | 67 (65-69) | 30 (29-31) | 1.0 (0.9-1.0) | 1.1 (1.0-1.2) | 30 | 32 | |
| No HHW | 683 | 6042 | χ2 | 37 (33-38) | 68 (67-69) | 1.1 (1.0-1.2) | 0.9 (0.9-1.0) | 32 | 28 | |||||||||
| 5186 | 19 538 | Limited physical activity | 3298 | 6867 | NA | 64 (2-65) | 35 (34-36) | 1.0 (1.0-1.0) | 1.0 (1.0-1.1) | 30 | 30 | |||||||
| Nocturia, incontinence, urinary urgency, or difficulty Self-report | Stewart et al | III | 84.6 | Retro (12) | Any fall | W: 79.9 (4.6) | 254 | 1254 | ≥2 nocturia | 141 | 688 | OR = 1.8 | 56 (49-62) | 55 (52-58) | 1.2 (1.1-1.4) | 0.8 (0.7-0.9) | 34 | 26 |
| Coll-Planas et al | I | 76.9 | Pro (12) | Any fall | 82 (NR) | 116 | 76 | ≥2 nocturia | 46 | 48 | OR = 1.1 | 40 (31-49) | 63 (51-74) | 1.1 (0.7-1.6) | 1.0 (0.8-1.2) | 32 | 30 | |
| Bongue et al | I | 84.6 | PRO (12) | Any fall | 70.7 (4.6) | 563 | 1196 | Yes | 108 | 1066 | OR = 1.9 | 19 (16-23) | 89 (87-91) | 1.8 (1.4-2.2) | 0.9 (0.9-1.0) | 44 | 28 | |
| Hellstrom et al | III | 100 | Retro (6) | Any fall | 81.7 (4.8) | 81 | 297 | Yes | 19 | 254 | χ2 | 23 (15-34) | 86 (81-89) | 1.6 (1.0-2.6) | 0.9 (0.8-1.0) | 41 | 28 | |
| Huang | III | 76.9 | Retro (12) | Any fall | F: 81.3 (5.1) | 195 | 202 | Yes | 66 | 160 | χ2 | 34 (27-41) | 79 (73-85) | 1.6 (1.2-2.3) | 0.8 (0.7-0.9) | 41 | 26 | |
| de Rekeneire | III | 69.2 | Retro (12) | Any fall | Range: 70-79 | 652 | 2398 | Yes | 314 | 1537 | χ2 | 48 (44-52) | 64 (62-66) | 1.3 (1.2-1.5) | 0.8 (0.8-0.9) | 36 | 26 | |
| Flemming | III | 69.2 | Retro (4) | Any fall | 78.7 (7.2) | 40 | 267 | Yes | 16 | 195 | χ2 | 40 (25-57) | 73 (67-78) | 1.5 (1.0-1.3) | 0.8 (0.6-1.1) | 39 | 26 | |
| Coll-Planas et al | I | 76.9 | Pro (12) | Any fall | 82 (NR) | 116 | 76 | Yes | 57 | 46 | OR = 1.5 | 49 (40-59) | 61 (49-72) | 1.2 (0.9-1.7) | 0.8 (0.7-1.1) | 60 | 26 | |
| Iinattiniemi et al | III | 69.2 | Retro (11) | Any fall | 88 (2) | 273 | 282 | Yes | 30 | 267 | χ2 | 11 (8-15) | 95 (91-97) | 2.1 (1.1-3.8) | 0.9 (0.9-1.0) | 47 | 28 | |
| 2290 | 6048 | Any urinary difficulty | 797 | 14 261 | NA | 35 (33-37) | 70 (69-72) | 1.2 (1.1-1.3) | 0.9 (0.9-1.0) | 34 | 26 | |||||||
| Pain Self-report | Kwan et al | I | 84.6 | Pro (24) | Fall inj/≥2 falls | 74.9 (6.4) | 86 | 174 | Significant | 45 | 134 | NR | 47 (36-58) | 74 (67-80) | 1.8 (1.3-2.5) | 0.7 (0.6-0.9) | 44 | 23 |
| Polypharmacy ≥4 medications, self-report | Peeters et al | I | 93.3 | Pro (37) | ≥2 falls | F: 76.9 (6.9) | 325 | 1004 | ≥4 meds | 96 | 777 | χ2 | 30 (25-35) | 77 (75-80) | 1.3 (1.1-1.6) | 0.9 (0.8-1.0) | 36 | 28 |
| Kwan et al | I | 84.6 | Pro (24) | ≥2 falls | 74.9 (6.4) | 86 | 174 | ≥4 meds | 33 | 135 | NR | 38 (28-49) | 78 (71-84) | 1.7 (1.2-2.5) | 0.8 (0.7-1.0) | 42 | 26 | |
| Fall inj/≥2 falls | 74.9 (6.4) | 86 | 174 | ≥4 meds | 14 | 150 | NR | 16 (9-26) | 86 (80-91) | 1.2 (0.6-1.2) | 1.0 (0.9-1.1) | 34 | 30 | |||||
| Brauer et al | I | 84.6 | Pro (6) | Any fall | 71 (5) | 35 | 65 | ≥3 meds | 7 | 45 | χ2 | 20 (8-37) | 69 (57-80) | 0.7 (0.2-1.4) | 1.2 (0.9-1.5) | 23 | 34 | |
| Muir et al | I | 84.6 | Pro (12) | Any fall | 79.7 (5.3) | 59 | 58 | ≥4 meds | 48 | 13 | NR | 81 (69-90) | 22 (13-35) | 1.1 (0.9-1.3) | 0.8 (0.4-1.7) | 32 | 26 | |
| Coll-Planas et al | I | 76.9 | Pro (12) | Any fall | 82 (NR) | 116 | 76 | ≥5 meds | 74 | 32 | OR = 1.2 | 64 (54-73) | 42 (31-54) | 1.1 (0.9-1.4) | 0.9 (0.6-1.3) | 32 | 28 | |
| Swanenburg et al | I | 76.9 | Pro (12) | ≥2 falls | 73.7 (7) | 85 | 185 | ≥4 meds | 54 | 110 | NR | 64 (52-74) | 59 (52-67) | 1.6 (1.2-2.0) | 0.6 (0.5-0.8) | 41 | 20 | |
| Muir et al | I | 76.9 | Pro (12) | Any fall | 79.9 (4.7) | 78 | 104 | ≥4 meds | 64 | 35 | NR | 82 (72-90) | 34 (25-44) | 1.2 (1.0-1.5) | 0.5 (0.3-0.9) | 34 | 18 | |
| LeClerc et al | I | 76.9 | Pro (6) | ≥2 falls | F: 79.6 (6.6) | 99 | 769 | ≥4 meds | 91 | 99 | χ2 | 92 (85-96) | 13 (11-15) | 1.1 (1.0-1.1) | 0.6 (0.3-1.3) | 32 | 20 | |
| Buatois et al | II | 69.2 | Pro (18) | ≥2 falls | 70.1 (4.4) | 96 | 903 | ≥4 meds | 52 | 569 | χ2 | 54 (44-64) | 63 (60-67) | 1.5 (1.2-1.8) | 0.7 (0.6-0.9) | 39 | 23 | |
| Payne et al | III | 92.3 | Retro (12) | Any fall | R: 75.5 (7.7) | 34 | 81 | ≥6 meds | 10 | 47 | NR | 29 (15-48) | 58 (47-69) | 0.7 (0.4-1.3) | 1.2 (0.9-1.6) | 23 | 34 | |
| Sai et al | III | 92.3 | Retro (12) | Any fall | 76.7 (6.1) | 95 | 42 | ≥4 meds | 35 | 35 | NR | 37 (27-47) | 83 (69-93) | 2.2 (1.2-4.6) | 0.8 (0.6-0.9) | 49 | 26 | |
| Perracini et al | III | 84.6 | Retro (12) | Any fall | F-LA 87/MA 79 | 68 | 54 | ≥5 meds | 41 | 30 | χ2 | 60 (48-72) | 56 (41-69) | 1.4 (1.0-1.9) | 0.7 (0.5-1.0) | 38 | 23 | |
| Shumway-Cook et al | III | 84.5 | Retro (6) | Any fall | F: 86.2 (6.4) | 15 | 15 | ≥4 meds | 2 | 15 | NR | 13 (2-40) | 100 (78-100) | NA | 0.9 (0.7-1.1) | NA | 28 | |
| Huang | III | 76.9 | Retro (12) | Any fall | F: 81.3 (5.1) | 190 | 190 | ≥4 meds | 78 | 129 | χ2 | 41 (34-48) | 70 (63-76) | 1.4 (1.0-1.8) | 0.9 (0.7-1.0) | 38 | 28 | |
| Flemming | III | 69.2 | Retro (4) | Any fall | 78.7 (7.2) | 40 | 267 | ≥4 meds | 34 | 71 | χ2 | 85 (70-94) | 27 (21-32) | 1.2 (1.0-1.3) | 0.6 (0.3-1.2) | 34 | 20 | |
| 1507 | 4161 | ≥4 meds | 733 | 2292 | NA | 48 (46-51) | 55 (54-57) | 1.1 (1.0-1.2) | 0.9 (0.9-1.0) | 32 | 28 | |||||||
| Psychoactive medications Self-report (yes/no) | Beauchet et al | I | 92.3 | Pro (12) | Any fall | 84.8 (5.2) | 54 | 133 | Any | 30 | 67 | χ2 | 56 (41-69) | 50 (42-59) | 1.1 (0.8-1.5) | 0.9 (0.6-1.3) | 32 | 28 |
| Peeters et al | I | 93.3 | Pro (37) | ≥2 falls | F: 76.9 (6.9) | 325 | 1004 | Any | 67 | 877 | χ2 | 21 (16-26) | 89 (86-90) | 1.8 (1.4-2.4) | 0.9 (0.8-1.0) | 44 | 28 | |
| Bongue et al | I | 84.6 | Pro (12) | Any fall | 70.7 (4.6) | 563 | 1196 | Any | 135 | 1030 | NR | 24 (21-27) | 86 (84-88) | 1.7 (1.4-2.1) | 0.9 (0.8-0.9) | 42 | 28 | |
| Kwan et al | I | 84.6 | Pro (24) | Fall inj/≥2 falls | 74.9 (6.4) | 86 | 174 | Any | 7 | 165 | NR | 8 (3-16) | 95 (90-98) | 1.6 (0.6-4.1) | 1.0 (0.9-1.0) | 41 | 30 | |
| Peeters et al | I | 84.6 | Pro (36) | Any Fall | 1F: 74.9 (6.4) ≥2F: 77.0 (6.9) | 740 | 597 | Any | 81 | 535 | χ2 | 11 (9-13) | 90 (87-92) | 1.1 (0.8-1.4) | 1.0 (1.0-1.0) | 32 | 30 | |
| Tinetti et al | I | 84.6 | Pro (12) | Any fall | 76.9 (5.3) | 546 | 557 | Any | 89 | 512 | ANOVA | 16 (13-20) | 92 (89-94) | 2.0 (1.4-2.8) | 0.9 (0.9-1.0) | 46 | 28 | |
| LeClerc et al | II | 76.9 | Pro (6) | ≥2 falls | F: 79.5 (6.6) | 99 | 769 | Any | 50 | 406 | χ2 | 51 (40-61) | 53 (49-56) | 1.1 (0.9-1.3) | 0.9 (0.8-1.2) | 32 | 28 | |
| Buatois et al | II | 69.2 | Pro (18+) | ≥2 falls | 70.1 (4.4) | 96 | 903 | Any | 19 | 812 | χ2 | 20 (12-29) | 95 (88-92) | 2.0 (1.3-3.1) | 0.9 (0.8-1.0) | 46 | 28 | |
| Hellstrom et al | III | 100 | Retro (6) | Any fall | 81.7 (4.8) | 81 | 297 | Any | 62 | 218 | χ2 | 77 (66-85) | 73 (68-78) | 2.9 (2.3-3.6) | 0.3 (0.2-0.5) | 55 | 11 | |
| Huang | III | 76.9 | Retro (12) | Any fall | F: 81.3 (5.1) | 194 | 198 | Any | 44 | 176 | χ2 | 23 (17-29) | 87 (81-91) | 1.7 (1.1-2.7) | 0.9 (0.8-1.0) | 42 | 28 | |
| de Rekeneire | III | 69.2 | Retro (12) | Any fall | Range: 70-79 | 652 | 2398 | Any | 48 | 2288 | χ2 | 7 (5-10) | 95 (95-96) | 1.6 (1.2-2.2) | 1.0 (0.9-1.0) | 41 | 30 | |
| Iinattiniemi et al | III | 69.2 | Retro (11) | Any fall | 88 (2) | 273 | 282 | Any | 118 | 187 | χ2 | 43 (37-49) | 66 (60-72) | 1.3 (1.0-1.6) | 0.9 (0.8-1.0) | 36 | 28 | |
| 3709 | 8508 | Any | 750 | 7269 | NA | 22 (19-22) | 85 (85-86) | 1.4 (1.3-1.5) | 0.9 (0.9-1.0) | 38 | 26 | |||||||
| 3709 | 8508 | Any | 750 | 7269 | NA | 22 (19-22) | 85 (85-86) | 1.4 (1.3-1.5) | 0.9 (0.9-1.0) | 38 | 26 | |||||||
Abbreviations: AD, use of any assistive device; ADL, activities of daily living; ANOVA, analysis of variance; AUC, area under the curve; CI95, 95% confidence interval; Depend, dependence; F, faller/persons who fell; Fall inj, fall with injury; HHW, heavy house work; IADL, instrumental activities of daily living; LA, less active; IRR, Incident Rate Ratio; M, men in the sample; MA, more active; −, negative; +, positive; NA, not applicable; NF, nonfaller/persons who did not fall; NR, not reported; OR, odds ratio; Pro, prospective; QUADAS, Quality Assessment Tool for Diagnostic Accuracy Studies; R, rural; Retro, retrospective; ROC, receiver operating characteristic curve; SD, standard deviation; Sn, sensitivity; Sp, specificity; U, urban; W, women in the sample.
aPosttest probabilities are based on an assumption of a 30% pretest probability for future falls.
Summary of Findings for Determining Risk of Falls Using Self-Report Measures, Grouped by Construct Being Measureda
| Self-Report Measure | Author | Level | QUADAS Score | Study Type, mo | Fall Defined | Age (SD) | Fallers, N | Nonfallers, N | Cut Point | Fallers With +Test | Nongallers With −Test | Difference | Sn (CI95), % | Sp (CI95), % | +LR (CI95) | −LR (CI95) | Posttest | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| If +Test | If −Test | |||||||||||||||||
| Activity-Specific Balance Confidence Scale | Payne et al | III | 92.3 | Retro (12) | Any fall | R: 75.5 (7.7) | 34 | 81 | <60 | 12 | 71 | NR | 35 (20-53) | 88 (78-94) | 2.9 (1.4-6.0) | 0.7 (0.6-1.0) | 55 | 23 |
| Balance Self-Perception Test | Shumway-Cook et al | III | 76.9 | Retro (6) | ≥2 falls | F: 77.6 (7.8) | 22 | 22 | ≤50 | 16 | 18 | 73 (50-89) | 82 (60-95) | 4.0 (1.6-10) | 0.3 (0.2-0.7) | 63 | 11 | |
| Falls Efficacy Scale International | Delbaere et al | I | 92.3 | Pro (12) | ≥2 falls | 77.9 (4.6) | 166 | 334 | >21 | 103 | 181 | OR = 1.3 | 62 (54-69) | 54 (49-60) | 1.4 (1.2-1.6) | 0.7 (0.6-0.9) | 38 | 23 |
| Kwan et al | I | 84.6 | Pro (24) | Fall inj/≥2 falls | 74.9 (6.4) | 86 | 174 | ≥24 | 64 | 127 | NR | 74 (64-83) | 73 (66-79) | 2.8 (2.1-3.6) | 0.4 (0.2-0.5) | 54 | 14 | |
| 252 | 508 | ≥24 | 167 | 308 | NA | 66 (60-72) | 60 (56-65) | 1.7 (1.0-2.4) | 0.6 (0.1-0.2) | 42 | 20 | |||||||
| Falls Efficacy Scale-Modified | Payne et al | III | 92.3 | Retro (12) | Any fall | R: 75.5 (7.7) | 34 | 81 | <6 | 6 | 76 | NR | 21 (8-41) | 94 (86-98) | 3.5 (1.1-10) | 0.8 (0.7-1.0) | 60 | 26 |
| Falls Risk Assessment Questionnaire Ordinal 0-16 points | Flemming | III | 69.2 | Pro (3) | Any fall | F: 78.7 (7.2) | 40 | 267 | >8 | 216 | 51 | 75 (59-87) | 81 (76-85) | 3.9 (2.9-5.3) | 0.3 (0.2-0.5) | 63 | 11 | |
| Barthel index Ordinal 0-20 points | Stalenhoef et al | I | 84.6 | Pro (9) | Any fall | M: 7.2 (4.9) | 2F 46 | 192 | <19 | 22 | 180 | OR = 3.3 | 48 (38-59) | 94 (89-97) | 7.8 (4.3-14) | 0.6 (0.5-0.7) | 77 | 20 |
| Oars ADL Scale | Perracini et al | III | 84.6 | Retro (12) | Any fall | LA-F: 86.6 | 66 | 52 | >4 | 41 | 37 | 62 (49-74) | 71 (57-83) | 2.2 (1.4-3.4) | 0.5 (0.4-0.7) | 49 | 18 | |
| MMSE Ordinal 0-30 points | Beauchet et al | I | 92.3 | Pro (12) | Any fall | F: 85.7 (5.2) | 54 | 133 | <25 | 34 | 64 | 63 (49-76) | 52 (43-61) | 1.3 (1.0-1.7) | 0.7 (0.5-1.1) | 36 | 23 | |
| Shumway-Cook et al | III | 76.9 | Retro (6) | Any fall | F: 77.6 (7.8) | 22 | 33 | NR | 10 | 27 | χ2 | 45 (24-68) | 82 (65-93) | 2.5 (1.1-6.0) | 0.7 (0.4-1.0) | 52 | 23 | |
| 76 | 166 | <25 | 44 | 91 | NA | 58 (46-69) | 55 (47-63) | 1.3 (1.0-1.7) | 0.8 (0.6-1.0) | 36 | 26 | |||||||
| Short-Orientation Memory Concentration Test | Coll-Planas et al | I | 76.9 | Pro (12) | Any fall | 82 (NR) | 116 | 76 | ≥9 | 38 | 52 | OR = 1.1 | 33 (24-42) | 68 (57-79) | 1.0 (0.7-1.6) | 1.0 (0.8-1.2) | 30 | 30 |
| Center for Epidemiologic Studies Depression | Tinetti et al | I | 84.6 | Pro (12) | Any Fall | 76.9 (5.3) | 546 | 557 | ≥16 | 116 | 457 | ANOVA | 21 (18-25) | 82 (79-85) | 1.2 (0.9-1.5) | 1.0 (0.9-1.0) | 34 | 30 |
| de Rekeneire | III | 69.2 | Retro (12) | Any fall | Range: 70-79 | 652 | 2398 | ≥16 | 41 | 2292 | χ2 | 6 (5-8) | 96 (95-96) | 1.4 (1.0-2.0) | 1.0 (1.0-1.0) | 38 | 30 | |
| 1198 | 2955 | ≥16 | 157 | 2749 | NA | 13 (11-15) | 93 (92-94) | 1.9 (1.5-2.3) | 0.9 (0.9-1.0) | 45 | 28 | |||||||
| Geriatric Depression Scale-15 item | Beauchet et al | I | 92.3 | Pro (12) | Any fall | F: 85.7 (5.2) | 54 | 133 | >4 | 11 | 118 | χ2 | 20 (11-34) | 89 (82-94) | 1.8 (0.9-3.7) | 0.9 (0.8-1.0) | 44 | 28 |
| Kwan et al | I | 84.6 | Pro (24) | Any fall | 74.9 (6.4) | 86 | 174 | ≥6 | 28 | 146 | IRR = 1.82 | 33 (23-44) | 84 (78-89) | 2.0 (1.3-3.2) | 0.8 (0.7-0.9) | 46 | 26 | |
| Iinattiniemi et al | II | 69.2 | Pro (11) | Any fall | F: 88 (3) | 273 | 282 | >7 | 71 | 241 | χ2 | 26 (21-32) | 85 (81-89) | 1.8 (1.3-2.5) | 0.9 (0.8-0.9) | 44 | 28 | |
| 413 | 589 | ≥7 | 110 | 505 | NA | 27 (22-31) | 86 (83-88) | 1.9 (1.5-2.4) | 0.9 (0.8-0.9) | 45 | 28 | |||||||
| Bongue et al | I | 84.6 | Pro (12) | Any fall | 70.7 (4.6) | 563 | 1196 | ≥1 | 198 | 872 | OR = 1.5 | 35 (31-39) | 73 (71-75) | 1.3 (1.1-1.5) | 0.9 (0.8-1.0) | 36 | 28 | |
| Coll-Planas et al | I | 76.9 | Pro (12) | Any fall | 82 (NR) | 116 | 76 | ≥1 | 55 | 46 | OR = 1.5 | 48 (38-57) | 61 (49-72) | 1.2 (0.9-1.7) | 0.9 (0.7-1.1) | 34 | 28 | |
| 679 | 1272 | ≥1 | 253 | 918 | NA | 37 (34-41) | 72 (70-75) | 1.3 (1.2-1.5) | 0.9 (0.8-0.9) | 36 | 28 | |||||||
| Longitudinal study of Aging Physical | Peeters et al | I | 92.3 | Pro (36) | ≥2 falls | F: 76.8 (6.8) | 325 | 1004 | No HHW | 173 | 611 | χ2 | 63 (48-59) | 61 (58-64) | 1.4 (1.2-1.6) | 0.8 (0.7-0.9) | 38 | 26 |
| Peeters et al | 1 | 84.6 | Pro (12) | ≥2 falls | 77.9 (7.1) | 76 | 332 | >8 | 48 | 208 | ROC AUC = .65 | 63 (51-74) | 63 (57-68) | 1.7 (1.4-2.1) | 0.6 (0.4-0.8) | 42 | 20 | |
| SF-36 Physical Activity Subscale | Bohannon et al | III | 90 | Retro (24) | Any fall | F: 80.8 (7.2) | 29 | 29 | <72.5 | 27 | 19 | 93 (77-99) | 66 (46-82) | 2.7 (1.6-4.5) | 0.1 (0.0-0.4) | 54 | 4 | |
| Subjective risk rating for specific tasks | Hashidate et al | III | 77.9 | Retro (12) | Any fall | 65 and older | 17 | 13 | ≥2 | 14 | 7 | χ2 | 82 (57-96) | 54 (25-81) | 1.8 (1.0-3.3) | 0.3 (0.1-1.0) | 44 | 11 |
| Sickness Impact Profile (SIP-68) | Stalenhoef et al | I | 84.6 | Pro (9) | ≥2 falls | M: 77.2 (4.9) | 46 | 192 | ≥8 | 6 | 148 | OR = 2.5 | 13 (5-26) | 77 (70-83) | 0.6 (0.3-1.3) | 1.1 (1.0-1.3) | 20 | 3.2 |
| Self-rated health | Payne et al | III | 92.3 | Retro (12) | Any fall | R: 75.5 (7.7) | 34 | 81 | <5 | 8 | 64 | NR | 24 (11-41) | 79 (69-87) | 1.1 (0.5-2.4) | 1.0 (0.8-1.2) | 32 | 30 |
| <8 | 21 | 31 | NR | 62 (44-78) | 38 (28-50) | 1.0 (0.7-1.4) | 1.0 (0.6-1.7) | 30 | 30 | |||||||||
Abbreviations: ADL, activities of daily living; ANOVA, analysis of variance; AUC; CES-D, Center for Epidemiological Studies Depression; CI95, 95% confidence interval; F, fallers; fall inj, fall with injury;FES-I, Falls Efficacy Scale International; GDS, Geriatric Depression Scale; HHW, heavy house work; IRR; LA, less active; LASA-PAQ, Longitudinal Study of Aging Physical Activity Questionnaire; LR, likelihood ratio; MA, more active; MMSE, Mini-Mental State Questionnaire; NA, not applicable; NF, nonfallers; NR, not reported; −, negative; OARS, Older Adults Resources and Services; OR, odds ratio; +, positive; Pro, prospective; QUADAS, Quality Assessment Tool for Diagnostic Accuracy Studies; Retro, retrospective; R, rural; ROC; SD, standard deviation; SF-36, 36-item Short Form Health Survey; Sn, sensitivity; Sp, specificity; U, urban.
aPosttest probabilities are based on an assumption of a 30% pretest probability for future falls.
Summary of Findings for Determining Risk of Falls Using Performance-Based Functional Measuresa
| Functional Measure | Author | Level | QUADAS Score | Study Type, mo | Fall Defined | Age Mean (SD) | Fallers, N | Nonfallers, N | Cut Point | Fallers With +Test | Nonfallers With –Test | Difference | Sn (CI95), % | Sp (CI95), % | +LR (CI95) | −LR (CI95) | Posttest Probability | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| If +Test | If −Test | |||||||||||||||||
| Alternate Step Test Continuous, s | Tiedemann | I | 92.3 | Pro (12) | ≥2 falls | 80.4 (4.5) | 74 | 265 | ≥10 | 51 | 95
| 69 (57-79) | 64 (58-70) | 1.9 (1.5-2.4) | 0.5 (0.3-0.7) | 45 | 18 | |
| BBS | LeClerc et al | I | 76.9 | Pro (6) | ≥2 falls | F: 79.5 (6.6) | 99 | 769 | ≤30 | 19 | 703 | 19 (12-28) | 91 (89-93) | 2.2 (1.4-3.6) | 0.9 (0.8-1.0) | 49 | 28 | |
| Muir et al | I | 76.9 | Pro (12) | Any fall | 79.9 (4.7) | 78 | 104 | ≤50 | 43 | 62 | NR | 55 (43-66) | 60 (50-69) | 1.4 (1.0-1.9) | 0.8 (0.6-1.0) | 38 | 26 | |
| O'Brien et al | III | 76.9 | Retro (12) | Any fall | F: 76.0 (6.7) | 13 | 23 | ≤45 | 7 | 23 | MW-U | 54 (25-81) | 100 (85-100) | NA | 0.5 (0.3-0.8) | NA | 18 | |
| Shumway-Cook et al | III | 76.9 | Retro (6) | ≥2 falls | F: 77.6 (7.8) | 22 | 22 | ≤49 | 17 | 19 | 77 (55-92) | 86 (65-97) | 5.7 (1.9-16.6) | 0.3 (0.1-0.6) | 71 | 11 | ||
| 212 | 918 | ≤50 | 86 | 807 | NA | 41 (34-47) | 88 (85-90) | 3.4 (2.6-4.3) | 0.7 (0.6-0.80) | 59 | 23 | |||||||
| BBS and history of imbalance | Shumway-Cook et al | III | 76.9 | Retro (6) | ≥2 falls | F: 77.6 (7.8) | 22 | 22 | ≤42/no or | 20 | 18 | NR | 91 (71-99) | 82 (60-95) | 5.0 (2.0-12) | 0.1 (0.0-0.4) | 68 | 4 |
| Clinical Test of Sensory Organization and Balance | Ricci et al | III | 69.2 | Retro (12) | ≥2 falls | ≥2F: 74.8 (7.3) | 32 | 32 | EO-Firm <30 s | 1 | 32 | ANOVA | 3 (1-16) | 100 (89-100) | NA | 1.0 (0.9-1.0) | NA | 30 |
| EC-Firm A <30 s | 5 | 30 | ANOVA | 16 (5-33) | 94 (79-99) | 2.5 (0.5-12) | 0.9 (0.8-1.1) | 52 | 28 | |||||||||
| Dome-FOAM <30 s | 7 | 30 | ANOVA | 22 (9-40) | 94 (78-99) | 3.5 (0.8-16) | 0.8 (0.7-1.0) | 60 | 26 | |||||||||
| EO-FOAM <30 s | 6 | 32 | ANOVA | 19 (7-36) | 100 (89-100) | NA | 0.8 (0.7-1.0) | NA | 26 | |||||||||
| EC-FOAM <30 s | 16 | 26 | ANOVA | 50 (32-68) | 81 (64-93) | 2.7 (1.2-6.0) | 0.6 (0.4-0.9) | 54 | 20 | |||||||||
| Dome-FOAM <30 s | 13 | 26 | ANOVA | 41 (24-49) | 81 (64-93) | 2.2 (0.9-5.0) | 0.7 (0.5-1.0) | 49 | 23 | |||||||||
| Dynamic gait index | Weiss et al | I | 76.9 | Pro (6) | ≥2 falls | F: 77.9 (5.1) | 12 | 59 | NR | 4 | 58 | NR | 64 (41-83) | 98 (91-100) | 3.7 (5.2-26.9) | 0.7 (0.2-0.6) | 94 | 23 |
| III | 76.9 | Retro (6) | ≥2 falls | F: 77.9 (5.1) | 32 | 39 | NR | 12 | 35 | 38 (21-56) | 90 (76-97) | 3.7 (1.3-10.3) | 0.7 (0.5-0.9) | 61 | 23 | |||
| Shumway-Cook et al | III | 76.9 | Retro (6) | ≥2 falls | F: 77.6 (7.8) | 22 | 22 | 19 | 13 | 11 | 59 (36-79) | 64 (41-83) | 1.6 (0.9-3.1) | 0.6 (0.4-1.2) | 41 | 20 | ||
| Herman et al | III | 69.2 | Retro (12) | Any fall | 76.3 (NR) | 74 | 204 | ≤19 | 66 | 6 | 90 (81-96) | 3 (1-6) | 0.9 (0.9-1.0) | 3.3 (1.1-9.4) | 28 | 59 | ||
| 140 | 324 | ≤19 | 95 | 111 | NA | 68 (60-76) | 34 (29-40) | 1.0 (0.9-1.2) | 0.9 (0.7-.3)) | 30 | 28 | |||||||
| 66 | 120 | ≤19 | 29 | 107 | NA | 44 (32-57) | 89 (82-94) | 4.0 (2.3-7.3) | 0.6 (0.5-0.8) | 63 | 20 | |||||||
| Fullerton Advanced Balance Scale Ordinal 0-40 | Hernandez and Rose | III | 84.6 | Retro (12) | ≥2 falls | 77.0 (6.5) | 59 | 133 | 25 | 43 | 69 | 73 (60-84) | 52 (43-61) | 1.5 (1.2-1.9) | 0.5 (0.3-0.8) | 39 | 18 | |
| 5TSTS | Tiedemann | I | 92.3 | Pro (12) | ≥2 falls | 80.4 (4.5) | 80 | 282 | ≥12 s | 53 | 127 | 66 (55-76) | 45 (39-51) | 1.2 (1.0-1.5) | 0.8 (0.5-1.1) | 34 | 25 | |
| Buatois et al | II | 69.2 | Pro (≥18) | ≥2 falls | 70.1 (4.4) | 96 | 903 | ≥15 s | 58 | 582 | χ2 | 60 (50-70) | 64 (61-68) | 1.7 (1.4-2.0) | 0.6 (0.5-0.8) | 42 | 20 | |
| Buatois et al | II | 46.2 | Pro (18) | ≥2 falls | 70 (4) | 183 | 1775 | ≥15 s | 101 | 1146 | NR | 55 (48-63) | 65 (62-67) | 1.6 (1.4-1.8) | 0.7 (0.6-0.8) | 41 | 23 | |
| 359 | 2960 | ≥12 | 212 | 1858 | NA | 59 (54-64) | 63 (61-65) | 1.6 (1.4-1.8) | 0.7 (0.6-0.7) | 41 | 20 | |||||||
| One time sit to stand | Tiedemann | I | 92.3 | Pro (12) | ≥2 falls | 80.4 (4.5) | 45 | 170 | ≥1 s | 22 | 89 | 49 (34-64) | 52 (45-60) | 1.0 (07-1.4) | 1.0 (0.7-1.3) | 30 | 30 | |
| 30-s Sit-to-Stand Test | Cho et al | III | 69.2 | Retro (12) | Any fall | F: 72.1 (5.9) | 31 | 55 | 15 times | 20 | 46 | 65 (45-81) | 84 (71-92) | 3.9 (2.0-7.6) | 0.4 (0.3-0.7) | 63 | 15 | |
| Ability to sit to stand without UE use | de Rekeneire | III | 69.2 | Retro (12) | Any fall | Range: 70-79 | 652 | 2398 | Unable | 35 | 2333 | χ2 | 5 (4-7) | 97 (96-98) | 2.0 (1.3-3.0) | 1.0 (0.9-1.0) | 46 | 30 |
| Stride length | Van Swearingen et al | III | 92.3 | Retro (12) | ≥2 falls | 75.5 (7.3) | 53 | 31 | <87 | 34 | 24 | 64 (50-77) | 77 (59-90) | 2.8 (1.4-5.6) | 0.5 (0.3-0.7) | 55 | 18 | |
| Functional (anterior) reach | Stalenhoef et al | I | 84.6 | Pro (9) | ≥2 falls | M: 77.2 (4.9) W: 78.5 (5.2) | 46 | 192 | ≤15 cm | 19 | 180 | OR = 2.0 | 41 (27-57) | 94 (89-97) | 6.6 (3.5-12.6) | 0.6 (0.5-0.8) | 74 | 20 |
| O'Brien et al | III | 76.9 | Retro (12) | Any fall | F: 76.0 (6.7) | 13 | 23 | <22 cm | 8 | 20 | MW-U | 62 (32-86) | 87 (66-97) | 4.7 (1.5-14.7) | 0.4 (0.2-0.9) | 67 | 15 | |
| 59 | 215 | <22 cm | 27 | 200 | NA | 55 (40-69) | 93 (89-96) | 7.9 (4.6-13) | 0.5 (0.4-0.7) | 77 | 17 | |||||||
| Maximal step length (longest trial) (% height) continuous | Lindeman et al | I | 92.3 | Pro (12) | Any fall | F: 68.8 (6.0) | 30 | 26 | <0.66 | 21 | 18 | KS | 70 (51-85) | 69 (48-86) | 2.3 (1.2-4.2) | 0.4 (0.2-0.8) | 50 | 15 |
| Maximal step length (mean 5 trials) (% height) continuous | <0.64 | 23 | 16 | KS | 77 (58-90) | 62 (41-80) | 2.0 (1.2-3.4) | 0.4 (0.2-0.8) | 46 | 15 | ||||||||
| Minimal chair height | Kwan et al | III | 84.6 | Retro (12) | Any fall | 74.9 (6.4) | 81 | 199 | NR | 52 | 131 | Wilks lambda | 64 (53-75) | 66 (59-72) | 1.9 (1.5-2.4) | 0.5 (0.4-0.7) | 45 | 18 |
| Modified Gait Abnormality Rating Scale | Van Swearingen et al | III | 92.3 | Retro (12) | ≥2 falls | 75.5 (7.3) | 53 | 31 | >9 | 33 | 27 | 62 (48-75) | 87 (70-96) | 4.8 (1.9-12.3) | 0.4 (0.3-0.6) | 67 | 15 | |
| mGARS >9 with PPT <15 Combined | mGARS >9 and PPT <15 | 48 | 27 | NR | 91 (79-97) | 87 (70-96) | 7.0 (2.8-17.6) | 0.1 (0.1-0.3) | 75 | 4 | ||||||||
| Performance-Oriented Mobility Assessment (POMA/Tinetti) | Topper et al | I | 92.3 | Pro (12) | Any fall | 83 (6) | 58 | 37 | NR | 54 | 33 | KW | 93 (83-98) | 89 (75-97) | 8.6 (3.4-21.8) | 0.1 (0.0-0.2) | 79 | 4 |
| Panzer et al | I | 84.6 | Pro (12) | ≥2 falls | F: 80 (6) | 27 | 47 | <26/28 | 14 | 47 | NR | 52 (32-71) | 100 (92-100) | NA | 0.5 (0.3-0.7) | NA | 18 | |
| Tinetti et al | I | 84.6 | Pro (12) | Any fall | 79.6 (5.2) | 546 | 557 | <12/22 | 252 | 384 | ANOVA | 46 (42-50) | 69 (65-73) | 1.5 (1.3-1.7) | 0.8 (0.7-0.9) | 39 | 26 | |
| Raiche et al | I | 76.9 | Pro (12) | Any fall | 80.0 (4.4) | 53 | 172 | <36/40 | 37 | 83 | NR | 70 (56-82) | 48 (41-56) | 1.4 (1.1-1.7) | 0.6 (0.4-1.0) | 38 | 20 | |
| Avdic and Pecar | III | 61.5 | Retro (6) | ≥2 falls | 71.7 (5.6) | 21 | 56 | <17/26 | 20 | 49 | 95 (76-100) | 88 (76-95) | 7.6 (3.8-15.3) | 0.5 (0.1-0.4) | 77 | 18 | ||
| 705 | 869 | <25 | 377 | 596 | NA | 53 (50-57) | 69 (65-72) | 1.7 (1.5-1.9) | 0.7 (0.6-0.7) | 42 | 23 | |||||||
| Pick up 5-lb weight test | Tiedemann | I | 92.3 | Pro (12) | ≥2 falls | 80.4 (4.5) | 80 | 282 | Unable | 9 | 262 | χ2 | 11 (5-20) | 93 (89-96) | 1.6 (0.8-2.4) | 1.0 (0.9-1.0) | 41 | 30 |
| 7-item PPT | Van Swearingen et al | III | 92.3 | Retro (12) | ≥2 falls | 75.5 (7.3) | 53 | 31 | <15 | 42 | 22 | 79 (66-89) | 71 (52-(86) | 2.7 (1.6-4.8) | 0.3 (0.2-0.5) | 54 | 11 | |
| PPT <15 and mGARS >9 | mGARS >9 PPT <15 | 48 | 27 | NR | 91 (79-97) | 87 (70-96) | 7.0 (2.8-17.6) | 0.1 (0.1-0.3) | 75 | 4 | ||||||||
| PPA | Delbaere et al | I | 92.3 | Pro (12) | Any fall | 77.9 (4.6) | 166 | 334 | >0.6 | 116 | 148 | OR = 1.2 | 70 (62-77) | 44 (39-50) | 1.3 (1.1-1.4) | 0.7 (0.5-0.9) | 36 | 23 |
| Kwan et al | III | 84.6 | Retro (12) | Any fall | F: 68 (3) | 81 | 199 | NR | 46 | 113 | 57 (45-68) | 57 (50-64) | 1.3 (1.0-1.7) | 0.8 (0.6-1.0) | 36 | 26 | ||
| 247 | 533 | >0.6 | 162 | 261 | NA | 66 (59-71) | 49 (45-53) | 1.3 (1.1-1.5) | 0.7 (0.6-0.9) | 36 | 23 | |||||||
| SSWS | Tiedemann | I | 92.3 | Pro (12) | ≥2 falls | 80.4 (4.5) | 80 | 282 | <1.0 | 40 | 192 | 50 (39-61) | 68 (62-73) | 1.6 (1.2-1.2) | 0.7 (0.6-0.9) | 41 | 23 | |
| Vicarro et al | I | 76.9 | Pro (12) | Any fall | 74 (5.7) | 161 | 264 | < 1.0 | 126 | 72 | NR | 78 (71-84) | 27 (22-33) | 1.1 (1.0-1.2) | 0.8 (0.6-1.1) | 32 | 26 | |
| < 0.6 | 36 | 244 | NR | 22 (16-30) | 92 (89-95) | 2.9 (1.8-4.9) | 0.8 (0.8-0.9) | 55 | 26 | |||||||||
| DePasquale and Toscano | III | 92.3 | Retro (12) | Any fall | F: 83 (5.5) | 29 | 29 | <1.2 | 19 | 22 | 67 (46-82) | 76 (56-90) | 2.7 (1.4-5.5) | 0.5 (0.3-0.8) | 54 | 18 | ||
| Van Swearingen et al | III | 92.3 | Retro (24) | ≥2 falls | 75.5 (7.3) | 53 | 31 | <0.6 | 38 | 23 | 72 (58-83) | 74 (55-88) | 2.8 (1.5-5.2) | 0.4 (0.2-0.6) | 55 | 15 | ||
| 323 | 607 | <1.0 | 223 | 317 | NA | 69 (64-74) | 52 (48-56) | 1.5 (1.3-1.6) | 0.6 (0.5-0.7) | 39 | 20 | |||||||
| 214 | 295 | <0.06 | 74 | 267 | NA | 35 (28-42) | 91 (87-94) | 3.6 (2.5-5.4) | 0.7 (0.7-0.8) | 61 | 23 | |||||||
| Single-limb stance | Bongue et al | I | 84.6 | Pro (12) | Any fall | 70.7 (4.6) | 563 | 1196 | <12.7 | 343 | 587 | OR = 1.5 | 61 (57-65) | 49 (46-52) | 1.2 (1.1-1.3) | 0.8 (0.7-0.9) | 34 | 26 |
| Muir et al | I | 76.9 | Pro (12) | Any fall | 79.9 (4.7) | 78 | 104 | <10 | 58 | 48 | RR: 1.58 | 74 (63-84) | 46 (36-56) | 1.4 (1.1-1.7) | 0.6 (0.4-0.9) | 38 | 20 | |
| Buatois et al | II | 69.2 | Pro (18) | ≥2 falls | 70 (4) | 96 | 903 | <5 | 16 | 815 | χ2 | 17 (9.8-26) | 90 (88-92) | 1.7 (1.1-2.8) | 0.9 (0.8-1.0) | 42 | 28 | |
| Buatois et al | II | 46.2 | Pro (18) | ≥2 falls | 70 (4) | 183 | 1775 | <5 | 29 | 1594 | NR | 35 (25-46) | 90 (88-91) | 3.4 (2.5-4.7) | 0.7 (0.6-0.9) | 59 | 23 | |
| DePasquale and Toscano | III | 92.3 | Retro (24) | Any fall | F: 83.6 (5.6) | 29 | 29 | <6.5 | 14 | 26 | 48 (29-64) | 90 (73-98) | 4.7 (1.5-14.5) | 0.6 (0.4-0.8) | 67 | 20 | ||
| 641 | 1300 | <12.7 | 401 | 635 | NA | 63 (59-66) | 49 (47-52) | 1.2 (1.1-0.3) | 0.8 (0.7-0.9) | 34 | 26 | |||||||
| 308 | 2707 | <6.5 | 59 | 2435 | NA | 19 (15-24) | 90 (89-91) | 1.9 (1.5-2.5) | 0.9 (0.9-1.0) | 45 | 28 | |||||||
| Single-limb stance | Bongue et al | I | 84.6 | Pro (12) | Any fall | 70.7 (4.6) | 563 | 1196 | <7.6 | Non Dom 259 | Non Dom 781 | OR = 1.4 NR | 46 (42-50) | 65 (63-68) | 1.3 (1.2-1.5) | 0.8 (0.8-0.9) | 36 | 26 |
| UE mvt yes | UE mvt first | UE mvt first 5 s 714 | OR = 1.5 NR | 51 (46-55) | 60 (57-63) | 1.3 (1.1-1.4) | 0.8 (0.8-0.9) | 36 | 26 | |||||||||
| Spring Scale Test | DePasquale and Toscano | III | 92.3 | Retro (24) | Any fall | F: 83.5 (5.5) | 29 | 29 | <10% | 27 | 28 | 93 (77-99) | 97 (82-100) | 27 (3.9-185) | 0.1 (0.0-0.3) | 92 | 4 | |
| 8-Stair ascent time | Tiedemann | I | 92.3 | Pro (12) | ≥2 falls | 80.4 (4.5) | 80 | 282 | ≥5 | 43 | 163 | 54 (42-65) | 58 (52-64) | 1.3 (1.0-1.6) | 0.8 (0.6-1.0) | 36 | 26 | |
| 8-Stair descent time | 50 | 155 | 63 (51-73) | 55 (49-61) | 1.4 (1.1-1.7) | 0.7 (0.5-0.8) | 38 | 23 | ||||||||||
| # Steps in a half turn | Tiedemann | I | 92.3 | Pro (12) | ≥2 falls | 80.4 (4.5) | 80 | 282 | ≥4 steps | 62 | 79 | 78 (67-86) | 28 (23-34) | 1.1 (0.9-1.2) | 0.08 (0.5-1.3) | 32 | 26 | |
| Tandem stance | Muir et al | I | 76.9 | Pro (12) | Any fall | 79.9 (4.7) | 78 | 104 | <30 | 39 | 64 | NR | 50 (38-62) | 62 (52-71) | 1.3 (0.9-1.8) | 0.8 (0.6-1.1) | 36 | 26 |
| DePasquale and Toscano | III | 92.3 | Retro (24) | Any fall | F: 83.5 (5.5) | 29 | 29 | <22 | 21 | 22 | 72 (53-87) | 76 (56-90) | 3.0 (1.5-5.9) | 0.4 (0.2-0.7) | 56 | 15 | ||
| 107 | 133 | <30 | 60 | 86 | NA | 56 (46-66) | 65 (56-73) | 1.6 (1.2-2.1) | 0.7 (0.5-0.9) | 41 | 23 | |||||||
| Tandem walk (able/unable) | Sai et al | I | 92.3 | Pro (12) | Any fall | 76.7 (6.1) | 94 | 42 | Unable | 91 | 11 | NR | 96 (90-99) | 26 (14-42) | 1.3 (1.1-1.6) | 0.2 (0.1-0.5) | 36 | 8 |
| TUG | Beauchet et al | I | 92.3 | Pro (12) | Any Fall | 84.8 (5.2) | 54 | 133 | ≥20 | 44 | 49 | χ2
| 82 (69-91) | 37 (29-46) | 1.3 (1.1-1.6) | 0.5 (0.3-0.9) | 36 | 18 |
| Bongue et al | I | 84.6 | Pro (12) | Any fall | 70.7 (4.6) | 563 | 1196 | ≥11 | 193 | 894 | OR = 1.5 | 34 (30-38) | 75 (72-77) | 1.4 (1.2-1.6) | 0.9 (0.8-0.9) | 38 | 28 | |
| Buatois et al | II | 69.2 | Pro (≥18) | ≥2 falls | 70.1 (4.4) | 96 | 903 | ≥12 | 12 | 836 | χ2
| 13 (7-21) | 93 (91-94) | 1.7 (1.0-3.0) | 0.9 (0.9-1.0) | 42 | 28 | |
| Buatois et al | II | 46.2 | Pro (18) | ≥2 falls | 70 (4) | 183 | 1775 | ≥12 | 25 | 1650 | χ2
| 15 (10-21) | 93 (92-94) | 2.1 (1.4-3.1) | 0.9 (0.9-10) | 47 | 28 | |
| LeClerc et al | II | 76.9 | Pro (6) | ≥2 falls | 79.5 (6.9) | 99 | 769 | ≥30 | 22 | 631 | 25 (17-35) | 82 (80-85) | 1.4 (1.0-2.0) | 0.9 (0.8-1.1) | 38 | 28 | ||
| DePasquale and Toscan | III | 92.3 | Retro (24) | Any fall | F: 83.5 (5.5) | 29 | 29 | ≥7.4 | 23 | 27 | 79 (60-92) | 93 (77-99) | 11.5 (2.0-44.4) | 0.2 (0.1-0.5) | 83 | 8 | ||
| Payne et al | III | 92.3 | Retro (12) | Any fall | R: 75.5 (7.7) | 34 | 81 | >15 | 12 | 69 | NR | 35 (20-54) | 85 (76-92) | 2.4 (1.2-4.8) | 0.8 (0.6-1.0 | 51 | 26 | |
| Greany and DiFAbio | III | 84.6 | Retro (12) | Any fall | 82.6 (5.5) | 12 | 21 | ≥13.5 | 10 | 16 | ANOVA | 83 (52-98) | 76 (53-92) | 3.5 (1.6-7.8) | 0.2 (0.1-0.8) | 60 | 8 | |
| Huo | III | 84.6 | Retro (12) | Any fall | 66.3 (5.2) | 24 | 77 | ≥8 | 20 | 47 | 83 (63-95) | 61 (49-72) | 2.1 (1.5-3.0) | 0.3 (0.1-0.7) | 47 | 11 | ||
| Shumway-Cook et al | III | 84.6 | Retro (6) | ≥2 falls | F: 86.2 (6.4) | 15 | 15 | >13.5 | 13 | 13 | MANOVA | 87 (60-98) | 87 (60-98) | 6.5 (1.8-24.0) | 0.2 (1.8-24.0) | 74 | 8 | |
| O'Brien et al | III | 76.9 | Retro (12) | Any fall | F: 76.0 (6.7) | 13 | 23 | ≥20 | 8 | 23 | MW-U | 63 (32-86) | 100 (85-100) | NA | 0.4 (0.2-0.8) | NA | 15 | |
| Vicarro et al | III | 76.9 | Retro (12) | Any fall | 74 (5.6) | 161 | 264 | ≥15 | 42 | 242 | NR | 26 (19-34) | 92 (88-95) | 3.1 (1.9-5.0) | 0.8 (0.7-0.9) | 57 | 26 | |
| 53 | 106 | >7.4 | 43 | 32 | NA | 56 (46-66) | 65 (56-73) | 1.6 (1.2-1.2) | 0.7 (0.5-0.9) | 41 | 23 | |||||||
| 1230 | 5180 | >12 | 381 | 4465 | NA | 31 (28-34) | 85 (84-86) | 2.1 (1.9-2.4) | 0.8 (0.8-0.8) | 47 | 25 | |||||||
| TUG | Shumway-Cook et al | III | 84.6 | Retro (6) | ≥2 falls | F: 86.2 (6.4) NF: 78.4 (5.8) | 15 | 15 | DT-C >13.5 | 12 | 14 | MANOVA | 80 (52-96) | 93 (68-100) | 12.0 (1.8-87.1) | 0.2 (0.1-0.6) | 84 | 8 |
| DT-M >13.5 | 12 | 14 | MANOVA | 80 (52-96) | 93 (68-100) | 12.0 (1.8-81.1) | 0.2 (0.1-0.6) | 84 | 8 | |||||||||
Abbreviations: ANOVA, analysis of variance; BBS, Berg Balance Scale; CI95, 95% confidence interval; DGI, dynamic gait index; EC, eyes closed; EO, eyes open; F, fallers; Firm, tested while standing on firm supporting surface; FOAM, tested while standing on foam surface; KS, Kolmogorov-Smirnov test; KW, Kruskal-Wallis test; LR, likelihood ratio; MANOVA, multivariate analysis of variance; M, men; mGARS, Modified Gait Abnormality Rating Scale; Mvt, movement; MW-U, Mann-Whitney U test; NA, not applicable; NF, nonfallers; Non Dom, nondominant; NR, not reported; +, positive; −, negative; OR, odds ratio; Pro, prospective; PPA, Physiological Profile Assessment; PPT, Physical Performance Test; QUADAS, Quality Assessment Tool for Diagnostic Accuracy Studies; Retro, retrospective; Sn, sensitivity; Sp, specificity; SD, standard deviation; SSWS, self-selected walking speed; 5TSTS, 5 times sit to stand; TUG, Timed Up and Go; UE, upper extremity; W, women.
aPosttest probabilities are based on an assumption of a 30% pre-test probability for future falls.
Summary of Clinically Useful Indicators of Risk of 1 or More Future Falls Based on a PrTP of 30%a
| Category | Measure | Cut Point | +LR | −LR | PoTP, % If +Test | PoTP, % If −Test |
|---|---|---|---|---|---|---|
| Medical history questions | Any previous falls | Yes/no | 1.8 | 0.8 | 44 | 26 |
| Psychoactive medication | Yes/no | 1.4 | 0.8 | 38 | 26 | |
| Requiring any ADL assistance | Yes/no | 1.4 | 0.8 | 38 | 26 | |
| Self-report fear of falling | Yes/no | 1.4 | 0.9 | 38 | 28 | |
| Ambulatory assistive device use | Yes/no | 1.3 | 0.9 | 36 | 26 | |
| Self-report measures | Geriatric Depression Scale-15 | <6 points | 1.9 | 0.9 | 45 | 28 |
| Falls Efficacy Scale International | >24 points | 1.7 | 0.6 | 42 | 20 | |
| Performance-based functional measures | Berg Balance Scale | <50 points | 3.4 | 0.7 | 59 | 23 |
| Timed Up and Go Test | >11 s | 2.1 | 0.8 | 47 | 25 | |
| Single-limb stance eyes open | <6.5 s | 1.9 | 0.9 | 45 | 28 | |
| Five Times Sit-to-Stand Test | >12 s | 1.6 | 0.7 | 41 | 20 | |
| Self-selected walking speed | <1.0 m/s | 1.5 | 0.6 | 39 | 20 |
Abbreviations: +LR, positive likelihood ratio; −LR, negative likelihood ratio; PoTP, posttest probability; PrTP, pretest probability; +, test positive test result; −, test negative test result.
aTo the extent that tests are independent (unrelated) the PoTP of 1 positive test can be used as a new PrTP for the next positive test, etc., to develop a cumulative individualized risk estimate. Because the degree of relationship among tests is not clearly understood at this time, this strategy may inflate the cumulative risk estimate. Online resources such as www.easycalculation.com/statistics/post-test-probability.php can assist clinicians in quickly determining cumulative PoTP risk values.